Skip to main content
Top
Published in: Respiratory Research 1/2020

Open Access 01-12-2020 | Computed Tomography | Research

Characteristic chest CT findings for progressive cavities in Mycobacterium avium complex pulmonary disease: a retrospective cohort study

Authors: Yohei Oshitani, Seigo Kitada, Ryuya Edahiro, Kazuyuki Tsujino, Hiroyuki Kagawa, Kenji Yoshimura, Keisuke Miki, Mari Miki, Hiroshi Kida

Published in: Respiratory Research | Issue 1/2020

Login to get access

Abstract

Background

Although cavities are an important finding in Mycobacterium avium complex pulmonary disease (MAC-PD), there is little information regarding the types of cavities that indicate disease progression. This study was performed to identify cavity characteristics that were associated with disease progression in patients with MAC-PD.

Methods

This retrospective cohort study included 97 patients presenting with MAC-PD with cavities between December 2006 and June 2016. We compared initial and final computed tomography (CT) findings, classified 52 and 45 patients in the progressive and non-progressive cavity groups, respectively, and examined the progression-related imaging features in initial CT images. A progressive cavity was defined by more than two-fold increase in internal diameter or emergence of a new cavity around the initial cavity.

Results

Patients in the progressive group were older (p < 0.001), had a lower body mass index (p = 0.043), and showed higher diabetes complication rates (p = 0.005). The initial CT in the progressive group showed a longer maximum internal diameter of the cavity (p < 0.001) and higher rates of cavities close to the chest wall (p < 0.001), multiple cavities (p = 0.023), consolidation around the cavity (p < 0.001), atelectasis (p = 0.011), and pleural thickening (p < 0.001). Multivariable logistic regression analysis revealed that the maximum internal diameter of the cavity (odds ratio [OR]: 1.11, 95% confidence interval [CI]: 1.02–1.21; p=0.012) and consolidation around the cavity (OR: 16.15, 95% CI: 4.05–64.46; p < 0.001) were significantly associated with progressive cavities. In cavities with a maximum internal diameter of ≥10 mm and simultaneous consolidation, the probability of progression was as high as 96.2%. The 10-year mortality rates in the progressive and non-progressive cavity groups were 46.7 and 9.8% (p < 0.001), respectively, while the 10-year respiratory failure rates were 28.1 and 0%, respectively (p < 0.001).

Conclusions

Large cavity size and consolidation on CT showed strong relationships with disease progression, which led to respiratory failure and high mortality rate.
Appendix
Available only for authorised users
Literature
1.
go back to reference Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881–6.CrossRef Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881–6.CrossRef
2.
go back to reference Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med. 2007;176:306–13.CrossRef Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med. 2007;176:306–13.CrossRef
3.
go back to reference Thomson RM. NTM working group at Queensland TB control Centre and Queensland mycobacterial reference laboratory. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010;16:1576–83.CrossRef Thomson RM. NTM working group at Queensland TB control Centre and Queensland mycobacterial reference laboratory. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010;16:1576–83.CrossRef
4.
go back to reference Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. Nontuberculous mycobacteria network European trials group. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42:1604–13.CrossRef Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. Nontuberculous mycobacteria network European trials group. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42:1604–13.CrossRef
5.
go back to reference Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease. Japan Emerg Infect Dis. 2016;22:1116–7.CrossRef Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease. Japan Emerg Infect Dis. 2016;22:1116–7.CrossRef
6.
go back to reference Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;185:575–83.CrossRef Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;185:575–83.CrossRef
7.
go back to reference Kumagai S, Ito A, Hashimoto T, Marumo S, Tokumasu H, Kotani A, et al. Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study. BMC Infect Dis. 2017;17:436.CrossRef Kumagai S, Ito A, Hashimoto T, Marumo S, Tokumasu H, Kotani A, et al. Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study. BMC Infect Dis. 2017;17:436.CrossRef
8.
go back to reference Gochi M, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease. BMJ Open. 2015;5:e008058.CrossRef Gochi M, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease. BMJ Open. 2015;5:e008058.CrossRef
9.
go back to reference Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J. 2017;49:1600537.CrossRef Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J. 2017;49:1600537.CrossRef
10.
go back to reference Ahn CH, McLarty JW, Ahn SS, Ahn SI, Hurst GA. Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Am Rev Respir Dis. 1982;125:388–91.PubMed Ahn CH, McLarty JW, Ahn SS, Ahn SI, Hurst GA. Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Am Rev Respir Dis. 1982;125:388–91.PubMed
11.
go back to reference Research Committee of the British Thoracic Society. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up patients receiving standardized treatment. Int J Tuberc Lung Dis. 2002;67:628–34. Research Committee of the British Thoracic Society. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up patients receiving standardized treatment. Int J Tuberc Lung Dis. 2002;67:628–34.
12.
go back to reference Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72:ii1–64.CrossRef Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72:ii1–64.CrossRef
13.
go back to reference Asakura T, Hayakawa N, Hasegawa N, Namkoong H, Takeuchi K, Suzuki S, et al. Long-term outcome of pulmonary resection for nontuberculous mycobacterial pulmonary disease. Clin Infect Dis. 2017;65:244–51.CrossRef Asakura T, Hayakawa N, Hasegawa N, Namkoong H, Takeuchi K, Suzuki S, et al. Long-term outcome of pulmonary resection for nontuberculous mycobacterial pulmonary disease. Clin Infect Dis. 2017;65:244–51.CrossRef
14.
go back to reference Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.CrossRef Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.CrossRef
15.
go back to reference Kitada S, Kobayashi K, Ichiyama S, Takakura S, Sakatani M, Suzuki K, et al. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med. 2008;177:793–7.CrossRef Kitada S, Kobayashi K, Ichiyama S, Takakura S, Sakatani M, Suzuki K, et al. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med. 2008;177:793–7.CrossRef
16.
go back to reference Gadkowski LB, Stout JE. Cavitary pulmonary disease. Clin Microbiol Rev. 2008;21:305–33.CrossRef Gadkowski LB, Stout JE. Cavitary pulmonary disease. Clin Microbiol Rev. 2008;21:305–33.CrossRef
17.
go back to reference Kim TS, Koh WJ, Han J, Chung MJ, Lee JH, Lee KS, et al. Hypothesis on the evolution of cavitary lesions in nontuberculous mycobacterial pulmonary infection: thin-section CT and histopathologic correlation. AJR Am J Roentgenol. 2005;184:1247–52.CrossRef Kim TS, Koh WJ, Han J, Chung MJ, Lee JH, Lee KS, et al. Hypothesis on the evolution of cavitary lesions in nontuberculous mycobacterial pulmonary infection: thin-section CT and histopathologic correlation. AJR Am J Roentgenol. 2005;184:1247–52.CrossRef
18.
go back to reference Aksamit TR. Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med. 2002;23:643–53.CrossRef Aksamit TR. Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med. 2002;23:643–53.CrossRef
19.
go back to reference Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin study Group of France. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest. 1995;107:1035–40.CrossRef Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin study Group of France. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest. 1995;107:1035–40.CrossRef
20.
go back to reference Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996;153:1766–72.CrossRef Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996;153:1766–72.CrossRef
21.
go back to reference Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160:866–72.CrossRef Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160:866–72.CrossRef
22.
go back to reference Kobashi Y, Matsushima T. The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease. Intern Med. 2003;42:670–5.CrossRef Kobashi Y, Matsushima T. The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease. Intern Med. 2003;42:670–5.CrossRef
23.
go back to reference Fujiuchi S, Matsumoto H, Yamazaki Y, Nakao S, Takahashi M, Satoh K, et al. Analysis of chest CT in patients with Mycobacterium avium complex pulmonary disease. Respiration. 2003;70:76–81.CrossRef Fujiuchi S, Matsumoto H, Yamazaki Y, Nakao S, Takahashi M, Satoh K, et al. Analysis of chest CT in patients with Mycobacterium avium complex pulmonary disease. Respiration. 2003;70:76–81.CrossRef
24.
go back to reference Kuroishi S, Nakamura Y, Hayakawa H, Shirai M, Nakano Y, Yasuda K, et al. Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings. Eur Respir J. 2008;32:147–52.CrossRef Kuroishi S, Nakamura Y, Hayakawa H, Shirai M, Nakano Y, Yasuda K, et al. Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings. Eur Respir J. 2008;32:147–52.CrossRef
25.
go back to reference Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis. 1965;92:687–703.PubMed Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis. 1965;92:687–703.PubMed
26.
go back to reference Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol. 2007;45:4064–6.CrossRef Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol. 2007;45:4064–6.CrossRef
27.
go back to reference Kurashima A, Horibe M. Distribution of pulmonary Mycobacterium avium complex (MAC) disease cavities and their course under chemotherapy. Kekkaku. 2012;87:397–402 [in Japanese].PubMed Kurashima A, Horibe M. Distribution of pulmonary Mycobacterium avium complex (MAC) disease cavities and their course under chemotherapy. Kekkaku. 2012;87:397–402 [in Japanese].PubMed
28.
go back to reference Lee G, Lee KS, Moon JW, Koh WJ, Jeong BH, Jeong YJ, et al. Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. Ann Am Thorac Soc. 2013;10:299–306.CrossRef Lee G, Lee KS, Moon JW, Koh WJ, Jeong BH, Jeong YJ, et al. Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. Ann Am Thorac Soc. 2013;10:299–306.CrossRef
29.
go back to reference Hibiya K, Shigeto E, Iida K, Kaibai M, Higa F, Tateyama M, et al. Distribution of mycobacterial antigen based on differences of histological characteristics in pulmonary Mycobacterium avium infectious diseases--consideration of the extent of surgical resection from the pathological standpoint. Pathol Res Pract. 2012;208:53–8.CrossRef Hibiya K, Shigeto E, Iida K, Kaibai M, Higa F, Tateyama M, et al. Distribution of mycobacterial antigen based on differences of histological characteristics in pulmonary Mycobacterium avium infectious diseases--consideration of the extent of surgical resection from the pathological standpoint. Pathol Res Pract. 2012;208:53–8.CrossRef
Metadata
Title
Characteristic chest CT findings for progressive cavities in Mycobacterium avium complex pulmonary disease: a retrospective cohort study
Authors
Yohei Oshitani
Seigo Kitada
Ryuya Edahiro
Kazuyuki Tsujino
Hiroyuki Kagawa
Kenji Yoshimura
Keisuke Miki
Mari Miki
Hiroshi Kida
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-1273-x

Other articles of this Issue 1/2020

Respiratory Research 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.